Nanovibronix (NASDAQ:FEED – Get Free Report) and ReShape Lifesciences (OTCMKTS:RSLSD – Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Profitability
This table compares Nanovibronix and ReShape Lifesciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| ReShape Lifesciences | -668.58% | -163.22% | -52.10% |
Earnings and Valuation
This table compares Nanovibronix and ReShape Lifesciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $2.56 million | 1.04 | -$3.70 million | ($41.74) | -0.06 |
| ReShape Lifesciences | $610,000.00 | 0.00 | -$81.15 million | N/A | N/A |
Nanovibronix has higher revenue and earnings than ReShape Lifesciences.
Volatility & Risk
Nanovibronix has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Nanovibronix and ReShape Lifesciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| ReShape Lifesciences | 0 | 0 | 0 | 0 | 0.00 |
Given ReShape Lifesciences’ higher probable upside, analysts plainly believe ReShape Lifesciences is more favorable than Nanovibronix.
Institutional and Insider Ownership
16.4% of Nanovibronix shares are owned by institutional investors. 1.4% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Nanovibronix beats ReShape Lifesciences on 9 of the 10 factors compared between the two stocks.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
About ReShape Lifesciences
ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
